Pharsight

Qbrexza is owned by Journey.

Qbrexza contains Glycopyrronium Tosylate.

Qbrexza has a total of 8 drug patents out of which 0 drug patents have expired.

Qbrexza was authorised for market use on 28 June, 2018.

Qbrexza is available in cloth;topical dosage forms.

Qbrexza can be used as topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older.

The generics of Qbrexza are possible to be released after 28 February, 2033.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10548875	JOURNEY	Glycopyrrolate salts	Feb, 2033 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10052267	JOURNEY	Topical glycopyrrolate formulations	Oct, 2028 (5 years from now)
US8618160	JOURNEY	Topical glycopyrrolate formulations	Dec, 2029 (6 years from now)
US9744105	JOURNEY	Topical glycopyrrolate formulations	Jul, 2030 (7 years from now)
US10004717	JOURNEY	Glycopyrrolate salts	Feb, 2033 (9 years from now)
US10543192	JOURNEY	Glycopyrrolate salts	Feb, 2033 (9 years from now)
US8859610	JOURNEY	Crystalline glycopyrrolate tosylate	Feb, 2033 (9 years from now)
US9259414	JOURNEY	Glycopyrrolate salts	Feb, 2033 (9 years from now)